Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs

被引:2
|
作者
Reddy, Nishith R. [1 ,2 ]
Maachi, Hasna [3 ,9 ,10 ,11 ,12 ,13 ]
Xiao, Yini [1 ,2 ,3 ]
Simic, Milos S. [1 ,2 ]
Yu, Wei [1 ,2 ]
Tonai, Yurie [1 ,2 ]
Cabanillas, Daniela A. [1 ,2 ]
Serrano-Wu, Ella [1 ,2 ]
Pauerstein, Philip T. [1 ,4 ]
Tamaki, Whitney [5 ]
Allen, Greg M. [1 ,6 ,7 ,8 ]
Parent, Audrey V. [3 ]
Hebrok, Matthias [3 ,9 ,10 ,11 ,12 ,13 ]
Lim, Wendell A. [1 ,2 ,7 ]
机构
[1] Univ Calif San Francisco, UCSF Cell Design Inst, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Diabet Ctr, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA
[5] Univ Calif San Francisco, UCSF CoLabs, San Francisco, CA USA
[6] Univ Calif San Francisco, Parker Inst Canc Immunotherapy, San Francisco, CA USA
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94118 USA
[8] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[9] Univ Hosp Rechts Isar MRI, Ctr Organoid Syst, Garching, Germany
[10] Tech Univ Munich, Garching, Germany
[11] Helmholtz Munich, Inst Diabet Organoid Technol, Helmholtz Diabet Ctr, Neuherberg, Germany
[12] Tech Univ Munich, Munich Inst Biomed Engn MIBE, Garching, Germany
[13] German Ctr Diabet Res DZD, Neuherberg, Germany
关键词
IMMUNE CELLS; IMMUNOTHERAPY; RECOGNITION; CHALLENGES; CANCER;
D O I
10.1126/science.adl4793
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Immune homeostasis requires a balance of inflammatory and suppressive activities. To design cells potentially useful for local immune suppression, we engineered conventional CD4+ T cells with synthetic Notch (synNotch) receptors driving antigen-triggered production of anti-inflammatory payloads. Screening a diverse library of suppression programs, we observed the strongest suppression of cytotoxic T cell attack by the production of both anti-inflammatory factors (interleukin-10, transforming growth factor-beta 1, programmed death ligand 1) and sinks for proinflammatory cytokines (interleukin-2 receptor subunit CD25). Engineered cells with bespoke regulatory programs protected tissues from immune attack without systemic suppression. Synthetic suppressor T cells protected transplanted beta cell organoids from cytotoxic T cells. They also protected specific tissues from unwanted chimeric antigen receptor (CAR) T cell cross-reaction. Synthetic suppressor T cells are a customizable platform to potentially treat autoimmune diseases, organ rejection, and CAR T cell toxicities with spatial precision.
引用
收藏
页数:14
相关论文
共 44 条
  • [21] Synthetic CD4+ T cell-targeted antigen-presenting cells elicit protective antitumor responses
    Caserta, Stefano
    Alessi, Patrizia
    Guarnerio, Jlenia
    Basso, Veronica
    Mondino, Anna
    CANCER RESEARCH, 2008, 68 (08) : 3010 - 3018
  • [22] SPECIFICITY OF THE RECOVERY ASSOCIATED SUPPRESSOR CELLS FOUND IN EAE OF LEWIS RATS - STUDIES WITH T-CELL LINES AND A SYNTHETIC ENCEPHALITOGENIC PEPTIDE (EP)
    VARRIALE, S
    BRANDLI, D
    BARBARIA, J
    BERAUD, E
    GOLDSTEIN, MM
    BERNARD, D
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1986, 13 (04) : 371 - 372
  • [23] Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study
    Sahlolbei, Maryam
    Azangou-Khyavy, Mohammadreza
    Khanali, Javad
    Khorsand, Babak
    Shiralipour, Aref
    Ahmadbeigi, Naser
    Madjd, Zahra
    Ghanbarian, Hossein
    Ardjmand, Alireza
    Hashemi, Seyed Mahmoud
    Kiani, Jafar
    HELIYON, 2023, 9 (09)
  • [24] Targeted deletion of liver myeloid derived suppressor cells by inhibition of STAT3 dependent survival pathways to rescue CAR-T function
    Gardell, Jillian
    Guha, Prajna
    Cunetta, Marissa
    Lima, Matthew
    Darpolor, Josephine
    Spat, N. Joseph
    Junghans, Richard P.
    Katz, Steven C.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [25] A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
    Curioni, A.
    Britschgi, C.
    Hiltbrunner, S.
    Bankel, L.
    Gulati, P.
    Weder, W.
    Opitz, I.
    Lauk, O.
    Caviezel, C.
    Knuth, A.
    Munz, C.
    Renner, C.
    Stahel, R. A.
    Petrausch, U.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] CRISPR-CAR Lentiviral Vector Coupling Transgene Expression with Targeted Cas9 Cleavage for the Engineering of Universal T Cells
    Preece, R.
    Georgiadis, C.
    Etuk, A.
    Qasim, W.
    HUMAN GENE THERAPY, 2019, 30 (02) : A7 - A7
  • [27] ENGINEERING OF SYNTHETIC CHEMOKINE RECEPTORS INTO IPSC-DERIVED CAR-T CELLS TO INCREASE HOMING AND ENHANCE TRAFFICKING INTO SOLID TUMORS
    Shirinbak, Soheila
    Grant, Joy
    Gentile, Angela
    Shrestha, Bishwas
    Chu, Philip
    Mehta, Amit
    Pan, Yijia
    Gaertner, Bjoern
    Pribadi, Mochtar
    Yao, Joyee
    Denholtz, Matthew
    Witty, Alec
    Smith, Layton
    Lee, Tom
    Peralta, Eigen
    Hosking, Martin
    Valamehr, Bob
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A291 - A291
  • [28] Engineering of allogeneic regulatory T cells expressing a CAR (Allo-CAR-Tregs) using ZFNmediated editing and AAV6 targeted integration
    Monteferrario, D.
    Tadi, S.
    Dupont, C.
    Jeanneau, C.
    Saviane, G.
    Marchetti, I.
    Lara, G.
    Rouquier, S.
    Ayrault, M.
    Gertner-Dardenne, J.
    de la Rosa, M.
    Fenard, D.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A142 - A143
  • [29] Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor - Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models
    Benmebarek, M.
    Karches, C.
    Schmidbauer, M.
    Kurzay, M.
    Klaus, R.
    Geiger, M.
    Rataj, F.
    Cadilha, B.
    Keyl, J.
    Lesch, S.
    Heise, C.
    Murr, R.
    vom Berg, J.
    Jastroch, M.
    Lamp, D.
    Niederfellner, G.
    Sustmann, C.
    Endres, S.
    Klein, C.
    Kobold, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S20 - S20
  • [30] Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells
    Jesus Corria-Osorio
    Santiago J. Carmona
    Evangelos Stefanidis
    Massimo Andreatta
    Yaquelin Ortiz-Miranda
    Tania Muller
    Ioanna A. Rota
    Isaac Crespo
    Bili Seijo
    Wilson Castro
    Cristina Jimenez-Luna
    Leonardo Scarpellino
    Catherine Ronet
    Aodrenn Spill
    Evripidis Lanitis
    Pedro Romero
    Sanjiv A. Luther
    Melita Irving
    George Coukos
    Nature Immunology, 2023, 24 : 869 - 883